CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Major Shareholder Bioventures Opportunities G. Yk Sells 1,236,874 Shares

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) major shareholder Bioventures Opportunities G. Yk sold 1,236,874 shares of the firm’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $0.12, for a total transaction of $148,424.88. Following the sale, the insider now owns 21,383,909 shares of the company’s stock, valued at approximately $2,566,069.08. The trade was a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

CERo Therapeutics Trading Down 18.1 %

Shares of NASDAQ CERO traded down $0.02 during midday trading on Tuesday, hitting $0.09. The company’s stock had a trading volume of 16,480,674 shares, compared to its average volume of 20,468,281. CERo Therapeutics Holdings, Inc. has a 1 year low of $0.06 and a 1 year high of $12.80. The business’s fifty day simple moving average is $0.13 and its two-hundred day simple moving average is $0.23.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.